Indaptus Therapeutics, Inc. Common Stock (INDP)
Indaptus Therapeutics, Inc. is a biotechnology company focused on developing innovative immuno-oncology and infectious disease therapies. The company leverages its proprietary INDP-001 platform to create targeted treatments aimed at stimulating the immune system to fight cancer and infectious diseases. Headquartered in the United States, Indaptus aims to advance therapies that address unmet medical needs through cutting-edge research and development.
Company News
Indaptus Therapeutics, a clinical-stage biotechnology company, highlights its accomplishments in 2024 and outlines its strategic goals for 2025, including the launch of a combination trial with BeiGene's tislelizumab and the expansion of its Decoy20 clinical trial.
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. Butterfly Network posted GAAP loss of 21 cents per share versus market estimates for a loss of 14 cents per share. The company’s quarterly sales came in at sales came in $16.52 million ve...
Indaptus (INDP) announces positive pre-clinical efficacy data from a poster presentation made at a scientific conference from its proprietary Decoy platform pre-clinical study. Stock is up 22%.
Here are three penny stocks for your watchlist right now The post Hot Penny Stocks to Watch Right Now? 3 For Your List in May appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.